These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34852352)

  • 21. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
    CORIMUNO-19 Collaborative group
    Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
    Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
    Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19.
    Dalekos GN; Stefos A; Georgiadou S; Lygoura V; Michail A; Ntaios G; Samakidou A; Giannoulis G; Gabeta S; Vlychou M; Petinaki E; Leventogiannis K; Giamarellos-Bourboulis EJ; Gatselis NK
    Eur J Intern Med; 2021 Jun; 88():52-62. PubMed ID: 33820686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients.
    Monti G; Campochiaro C; Zangrillo A; Scandroglio AM; Fominskiy E; Cavalli G; Landoni G; Beretta L; Mucci M; Calabrò MG; Pieri M; Nardelli P; Sartorelli M; Baiardo Redaelli M; Morselli F; Serpa Neto A; Bellomo R; Dagna L;
    Minerva Anestesiol; 2021 Aug; 87(8):891-902. PubMed ID: 34102804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study.
    Coloretti I; Busani S; Biagioni E; Venturelli S; Munari E; Sita M; DallAra L; Tosi M; Clini E; Tonelli R; Fantini R; Mussini C; Meschiari M; Guaraldi G; Cossarizza A; Alfano G; Girardis M
    Multidiscip Respir Med; 2021 Jan; 16(1):737. PubMed ID: 34040779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
    Başaran S; Şimşek-Yavuz S; Meşe S; Çağatay A; Medetalibeyoğlu A; Öncül O; Özsüt H; Ağaçfidan A; Gül A; Eraksoy H
    Int J Infect Dis; 2021 Apr; 105():756-762. PubMed ID: 33737128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current evidence on the use of anakinra in COVID-19.
    Khani E; Shahrabi M; Rezaei H; Pourkarim F; Afsharirad H; Solduzian M
    Int Immunopharmacol; 2022 Oct; 111():109075. PubMed ID: 35905562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome.
    Taher A; Lashgari M; Sedighi L; Rahimi-Bashar F; Poorolajal J; Mehrpooya M
    Pharmacol Rep; 2021 Dec; 73(6):1650-1659. PubMed ID: 34114174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.
    Villar J; Añón JM; Ferrando C; Aguilar G; Muñoz T; Ferreres J; Ambrós A; Aldecoa C; Suárez-Sipmann F; Thorpe KE; Jüni P; Slutsky AS;
    Trials; 2020 Aug; 21(1):717. PubMed ID: 32799933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome.
    Segú-Vergés C; Artigas L; Coma M; Peck RW
    PLoS One; 2023; 18(2):e0280677. PubMed ID: 36791125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].
    Muñoz-Jiménez A; Rubio-Romero E; Marenco de la Fuente JL
    Reumatol Clin (Engl Ed); 2021; 17(6):309-312. PubMed ID: 32482538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial.
    Tomazini BM; Maia IS; Bueno FR; Silva MVAO; Baldassare FP; Costa ELV; Moura RAB; Honorato MO; Costa AN; Cavalcanti AB; Rosa RG; Avezum Á; Veiga VC; Lopes RD; Damiani LP; Machado FR; Berwanger O; Azevedo LCP;
    Rev Bras Ter Intensiva; 2020; 32(3):354-362. PubMed ID: 33053024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
    Corominas H; Castellví I; Pomar V; Antonijoan R; Mur I; Matas L; Gich I; de Benito N; Laiz A; Castillo D; Villamarin L; Filella D; Millán AM; Quijada MÁ; Puig M; Casademont J; Domingo P
    Clin Immunol; 2021 Feb; 223():108631. PubMed ID: 33189888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.
    Rajasekaran S; Kruse K; Kovey K; Davis AT; Hassan NE; Ndika AN; Zuiderveen S; Birmingham J
    Pediatr Crit Care Med; 2014 Jun; 15(5):401-8. PubMed ID: 24583503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab.
    Figuero-Pérez L; Olivares-Hernández A; Escala-Cornejo RA; Terán-Brage E; López-Gutiérrez Á; Cruz-Hernández JJ
    Reumatol Clin (Engl Ed); 2021 Dec; 17(10):559-561. PubMed ID: 34823820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.